Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF CANCER
Volume 170, Issue -, Pages 73-84
Publisher
Elsevier BV
Online
2022-05-19
DOI
10.1016/j.ejca.2022.04.016
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
- (2021) Johann S de Bono et al. LANCET ONCOLOGY
- TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).
- (2020) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
- (2020) Richard T. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel
- (2020) Domenica Lorusso et al. SUPPORTIVE CARE IN CANCER
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
- (2020) Seock-Ah Im et al. Scientific Reports
- Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
- (2020) Wassim Abida et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
- (2020) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
- (2019) M E Robson et al. ANNALS OF ONCOLOGY
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA50Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)
- (2019) M R Smith et al. ANNALS OF ONCOLOGY
- Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
- (2018) Michael Friedlander et al. BRITISH JOURNAL OF CANCER
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment
- (2018) Norbaini Abdol Razak et al. Cancers
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer
- (2017) Jing Wu et al. Oncotarget
- Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy
- (2015) Sean O'Farrell et al. BJU INTERNATIONAL
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance
- (2015) Peter Bai MOLECULAR CELL
- Parp-2 is required to maintain hematopoiesis following sublethal -irradiation in mice
- (2013) J. Farres et al. BLOOD
- Hematological changes during androgen deprivation therapy
- (2012) Mathis Grossmann et al. ASIAN JOURNAL OF ANDROLOGY
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human
- (2011) Michael M Morgan et al. BRITISH JOURNAL OF PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started